Restorbio, Inc.
ACET US0070021086
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Kauffman Michael |
1.43 USD |
5,900 Sold |
8,437 USD |
05/06/2024 | 05/06/2024 |
Gordon Carl L |
2.40 USD |
1,841,100 Bought |
4,418,640 USD |
25/01/2024 | 25/01/2024 |
Gordon Carl L |
2.40 USD |
242,200 Bought |
581,280 USD |
25/01/2024 | 25/01/2024 |
Gordon Carl L |
2.40 USD |
1,041,700 Bought |
2,500,080 USD |
25/01/2024 | 25/01/2024 |